Ali Ahsan T, Kalapatapu Venkat R, Bledsoe Shelly, Moursi Mohammed M, Eidt John F
Departments of Surgery and Radiology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Vasc Endovascular Surg. 2005 Nov-Dec;39(6):491-7. doi: 10.1177/153857440503900605.
Patients with severe tibioperoneal disease are poor candidates for a distal bypass. Absence of a distal target, lack of conduit, or multiple medical problems can make these patients a prohibitive risk for revascularization. Acute on chronic ischemia in this group poses a greater challenge. Thrombolytic therapy for acute ischemia can be prolonged and carries a significant risk of bleeding if continued beyond 24 hours. However, if the ischemic limbs can be isolated from the systemic circulation, a higher dose of the lytic agent can be given with lower risk. These are the initial results of a series of 10 patients who underwent percutaneous isolated limb perfusion with a high dose of thrombolytics for severe ischemia. Ten patients (lower extremity 8 and upper extremity 2) presented with severe limb-threatening ischemia. Mean ankle/brachial index (ABI) was 0.15 for the lower extremity, and there were no recordable digital pressures in patients with upper extremity ischemia. No distal target was visible on the initial arteriogram. These patients were then taken to the operating room, and under anesthesia, catheters were placed in an antegrade fashion via femoral approach in the popliteal artery and vein percutaneously. For upper extremity, the catheters were placed in the brachial artery and vein. A proximal tourniquet was then applied. This isolated the limb from the systemic circulation. Heparinized saline was infused through the arterial catheter while the venous catheter was left open. A closed loop or an isolated limb perfusion was confirmed when effluent became clear coming out of the venous port. A high dose of thrombolytic agent (urokinase 500,000 to 1,000,000 U) was infused into the isolated limb via the arterial catheter and drained out of the venous catheter. After 45 minutes, arterial flow was reestablished. In 4 patients, Reopro((R)) was used in addition to thrombolytics. Postprocedure angiograms showed minimal changes, but patients exhibited marked clinical improvement. The ABI changed from 0.15 to 0.5 in the lower extremity and near-normal digital pressures in upper extremity ischemia. Limb salvage and symptomatic relief at 6 months was 90%. All patients except one were kept on anticoagulation postoperatively. No bleeding complications were observed from the procedure. Percutaneous isolated limb perfusion brought symptomatic relief to patients presenting with acute on chronic limb ischemia. This can be an alternate option for patients facing amputation with no revascularization options.
患有严重胫腓骨疾病的患者不太适合进行远端血管搭桥术。缺乏远端靶点、没有合适的血管 conduit 或存在多种内科问题会使这些患者进行血管重建的风险过高。该组患者慢性缺血基础上的急性缺血构成了更大的挑战。急性缺血的溶栓治疗可能会持续较长时间,如果超过24小时继续进行,会有显著的出血风险。然而,如果能将缺血肢体与体循环隔离开,就可以给予更高剂量的溶栓剂且风险更低。这是一系列10例因严重缺血接受经皮孤立肢体灌注高剂量溶栓剂治疗的患者的初步结果。10例患者(8例下肢,2例上肢)出现严重的肢体威胁性缺血。下肢平均踝肱指数(ABI)为0.15,上肢缺血患者没有可记录的指端血压。初始血管造影未见远端靶点。然后将这些患者送入手术室,在麻醉下,通过股动脉途径经皮将导管顺行置入腘动脉和静脉。对于上肢,导管置入肱动脉和静脉。然后应用近端止血带。这将肢体与体循环隔离开。通过动脉导管输注肝素化盐水,同时静脉导管保持开放。当静脉端口流出液变清时,确认形成闭环或孤立肢体灌注。通过动脉导管将高剂量的溶栓剂(尿激酶500,000至1,000,000单位)注入孤立肢体,并从静脉导管排出。45分钟后,重新建立动脉血流。4例患者除了使用溶栓剂外还使用了Reopro(商标名)。术后血管造影显示变化极小,但患者临床症状明显改善。下肢ABI从0.15变为0.5,上肢缺血患者指端血压接近正常。6个月时肢体挽救和症状缓解率为90%。除1例患者外,所有患者术后均持续抗凝。该手术未观察到出血并发症。经皮孤立肢体灌注为慢性肢体缺血基础上急性发作的患者带来了症状缓解。对于面临截肢且没有血管重建选择的患者,这可能是一种替代选择。 (注:文中“conduit”可能是指血管通道之类的医学术语,因缺乏更多背景信息,直接保留英文未翻译)